clinical trial · NCT07348601
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
Prader-Willi SyndromeCSTI-500
brief summary
This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.
started
Mar 1, 2026
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Jan 16, 2026
official title
A Proof-of-Concept Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of CSTI-500 in Participants With Prader-Willi Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol